Clinical Trials Logo

Polymyalgia Rheumatica clinical trials

View clinical trials related to Polymyalgia Rheumatica.

Filter by:

NCT ID: NCT00305539 Completed - Clinical trials for Giant Cell Arteritis

HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Start date: May 2006
Phase: Phase 3
Study type: Interventional

Hypothesis: In giant cell arteritis (GCA), a short initial treatment with anti-TNF may allow a faster decrease of steroids dosage and therefore avoid some of the adverse events of steroids.

NCT ID: NCT00138983 Completed - Clinical trials for Rheumatoid Arthritis

Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

Start date: May 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine wich treatment is the most effective in prevention of glucocorticoid-induced osteoporosis in patients with rheumatic diseases. The STOP-study: a randomized placebo controlled trial with alendronate versus alfacalcidol.

NCT ID: NCT00076726 Terminated - Clinical trials for Giant Cell Arteritis

A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis

Start date: November 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy (effectiveness) of Infliximab (Remicade) in patients with Giant Cell Arteritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

NCT ID: NCT00006055 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

Start date: March 2000
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II. Determine the kinetics of T- and B-cell immune reconstitution after a combination of timed plasmapheresis, high dose cyclophosphamide and total lymphoid irradiation, and posttransplant immunosuppression with cyclosporine in these patients. III. Determine whether this treatment regimen beneficially influences the clinical course of these patients.

NCT ID: NCT00004686 Completed - Clinical trials for Giant Cell Arteritis

Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis

Start date: February 1994
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Compare the long term outcomes in patients with giant cell arteritis after glucocorticoid treatment with or without methotrexate. II. Compare remission relapse rates in these patients after glucocorticoid therapy with or without methotrexate. III. Determine whether adjunctive use of methotrexate lowers cumulative dose and duration of glucocorticoid therapy and whether there is less treatment related morbidity and mortality. IV. Demonstrate the feasibility of long term, double blind, placebo controlled, randomized, multicenter trials for treatment of systemic vasculitides.